We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 22, 2018

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in HER2+ and HR+ Metastatic or Locally Advanced Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
J. Clin. Oncol 2018 Aug 14;[EPub Ahead of Print], M Rimawi, JM Ferrero, J de la Haba-Rodriguez, C Poole, S De Placido, CK Osborne, R Hegg, V Easton, C Wohlfarth, G Arpino

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading